Literature DB >> 23675763

An immunocytochemical-derived correlate for evaluating the bridging of heteromeric mu-delta opioid protomers by bivalent ligands.

Ajay S Yekkirala1, Alexander E Kalyuzhny, Philip S Portoghese.   

Abstract

Bivalent ligands that contain two pharmacophores linked by a spacer are promising tools to investigate the pharmacology of opioid receptor heteromers. Evidence for occupation of neighboring protomers by two phamacophores of a single bivalent ligand (bridging) has relied mainly on pharmacological data. In the present study, we have employed an immunocytochemical correlate to support in vivo biological studies that are consistent with bridging. We show that a bivalent mu agonist/delta antagonist (MDAN-21) that is devoid of tolerance due to possible bridging of mu and delta protomers prevents endocytosis of the heteromeric receptors in HEK-293 cells. Conversely, a bivalent ligand (MDAN-16) with a short spacer or monovalent mu agonist give rise to robust internalization. The data suggest that the immobilization of proximal mu and delta protomers is due to bridging by MDAN-21. The finding that MDAN-21 and its shorter spacer homologue MDAN-16 possess equivalent activity in HEK-293 cells, but produce dramatically divergent internalization of mu-delta heteromer, is relevant to the role of internalization and tolerance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23675763      PMCID: PMC5060010          DOI: 10.1021/cb400113d

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  28 in total

1.  Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties.

Authors:  S R George; T Fan; Z Xie; R Tse; V Tam; G Varghese; B F O'Dowd
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

2.  Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer.

Authors:  Danxin Wang; Xiaochun Sun; Laura M Bohn; Wolfgang Sadée
Journal:  Mol Pharmacol       Date:  2005-03-18       Impact factor: 4.436

3.  Trafficking of preassembled opioid mu-delta heterooligomer-Gz signaling complexes to the plasma membrane: coregulation by agonists.

Authors:  Ahmed Hasbi; Tuan Nguyen; Theresa Fan; Regina Cheng; Asim Rashid; Mohammad Alijaniaram; Mark M Rasenick; Brian F O'Dowd; Susan R George
Journal:  Biochemistry       Date:  2007-10-17       Impact factor: 3.162

Review 4.  Role of receptor internalization in opioid tolerance and dependence.

Authors:  Thomas Koch; Volker Höllt
Journal:  Pharmacol Ther       Date:  2007-11-17       Impact factor: 12.310

5.  Standard opioid agonists activate heteromeric opioid receptors: evidence for morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective μ-δ agonists.

Authors:  Ajay S Yekkirala; Alexander E Kalyuzhny; Philip S Portoghese
Journal:  ACS Chem Neurosci       Date:  2009-11-25       Impact factor: 4.418

6.  Opioid agonist and antagonist bivalent ligands as receptor probes.

Authors:  P S Portoghese; G Ronsisvalle; D L Larson; C B Yim; L M Sayre; A E Takemori
Journal:  Life Sci       Date:  1982 Sep 20-27       Impact factor: 5.037

Review 7.  The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence.

Authors:  Lene Martini; Jennifer L Whistler
Journal:  Curr Opin Neurobiol       Date:  2007-12-18       Impact factor: 6.627

8.  Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.

Authors:  Yaguo Zheng; Eyup Akgün; Kaleeckal G Harikumar; Jessika Hopson; Michael D Powers; Mary M Lunzer; Laurence J Miller; Philip S Portoghese
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

9.  Crystal structure of the µ-opioid receptor bound to a morphinan antagonist.

Authors:  Aashish Manglik; Andrew C Kruse; Tong Sun Kobilka; Foon Sun Thian; Jesper M Mathiesen; Roger K Sunahara; Leonardo Pardo; William I Weis; Brian K Kobilka; Sébastien Granier
Journal:  Nature       Date:  2012-03-21       Impact factor: 49.962

10.  In vivo delta opioid receptor internalization controls behavioral effects of agonists.

Authors:  Amynah A A Pradhan; Jérôme A J Becker; Grégory Scherrer; Petra Tryoen-Toth; Dominique Filliol; Audrey Matifas; Dominique Massotte; Claire Gavériaux-Ruff; Brigitte L Kieffer
Journal:  PLoS One       Date:  2009-05-01       Impact factor: 3.240

View more
  17 in total

Review 1.  Breaking barriers to novel analgesic drug development.

Authors:  Ajay S Yekkirala; David P Roberson; Bruce P Bean; Clifford J Woolf
Journal:  Nat Rev Drug Discov       Date:  2017-06-09       Impact factor: 84.694

Review 2.  Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.

Authors:  Wakako Fujita; Ivone Gomes; Lakshmi A Devi
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 3.  Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10.

Authors:  Wakako Fujita; Ivone Gomes; Lakshmi A Devi
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

Review 4.  Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.

Authors:  Nebojsa Nick Knezevic; Ajay Yekkirala; Tony L Yaksh
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

5.  A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH2 versus the Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH2: A Bivalent Advantage.

Authors:  Cody J Lensing; Danielle N Adank; Stacey L Wilber; Katie T Freeman; Sathya M Schnell; Robert C Speth; Adam T Zarth; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2017-02-16       Impact factor: 4.418

6.  OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects.

Authors:  Lisa R Gerak; David R Maguire; Gerta Cami-Kobeci; Keith M Olson; John R Traynor; Stephen M Husbands; Charles P France; Lisette Acevedo; Barbara Belli; Peter Flynn
Journal:  Behav Pharmacol       Date:  2022-08-03       Impact factor: 2.277

7.  An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.

Authors:  Cody J Lensing; Katie T Freeman; Sathya M Schnell; Danielle N Adank; Robert C Speth; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2016-03-29       Impact factor: 7.446

8.  Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.

Authors:  Morgan Le Naour; Eyup Akgün; Ajay Yekkirala; Mary M Lunzer; Mike D Powers; Alexander E Kalyuzhny; Philip S Portoghese
Journal:  J Med Chem       Date:  2013-06-20       Impact factor: 7.446

9.  Ligand requirements for involvement of PKCε in synergistic analgesic interactions between spinal μ and δ opioid receptors.

Authors:  D J Schuster; M D Metcalf; K F Kitto; R O Messing; C A Fairbanks; G L Wilcox
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

10.  Pharmacological Profiles of Oligomerized μ-Opioid Receptors.

Authors:  Cynthia Wei-Sheng Lee; Ing-Kang Ho
Journal:  Cells       Date:  2013-10-11       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.